



Press Release

Half Year Results 2026

- **Cash balance of €26.9 million as of June 30, 2026, before tax credits and grants under the France 2030 plan**
- **Focus on strategy execution and rigorous program implementation in LCAT Deficiency and sepsis**

Toulouse, FRANCE, Fullerton, CA, UNITED STATES, September 23, 2026, 8:00 p.m. CEST – ABIONYX Pharma, (FR0012616852 – ABNX – eligible for the PEA PME), a next-generation biopharmaceutical company developing innovative therapies for sepsis and critical care based on a proprietary apoA-I technology platform, today announced its financial results for the first half of 2026.

Key Developments in the Consolidated Financial Statements

As mentioned in the announcement of half-year revenue on August 27, the business dedicated to the discovery and development of innovative therapies—particularly for sepsis and the rare disease LCAT deficiency (also known as Norum disease)—aimed at improving or even saving patients' lives, has not yet generated any revenue during this half-year period. ABIONYX Pharma continues to provide its biopharmaceutical product free of charge in connection with applications for compassionate use authorization (AAC) for Norum disease.

The ABIONYX Pharma Group reported consolidated half-year revenue of €1.9 million for the first half of 2026, which is attributable solely to its subsidiary IRIS Pharma's contract research organization (CRO) activities in ophthalmology. Based on the information available as of the date of this press release, the Company anticipates that IRIS Pharma's revenue for fiscal year 2026 will remain broadly stable compared to that of fiscal year 2025.

As of June 30, 2026, research and development expenses totaled 570 K€, compared to 692 K€ as of June 30, 2025. Administrative and selling expenses totaled 1,807 K€ as of June 30, 2026, compared to 1,876 K€ as of June 30, 2025.

After accounting for these expenses, operating income improved from a loss of 2,330 K€ as of June 30, 2025, to a loss of 2,270 K€ as of June 30, 2026. The financial result was a loss of 2,543 K€ as of June 30, 2026, compared to a profit of 32 K€ in the first half of 2025. This financial result is attributable to the , fair-value measurement of financial debt related to the Fenja straight bonds (recognition of a financial expense of 1.6 million euros) and to the financial costs incurred during the issuance of these straight bonds. The net loss amounted to 4,814 K€ as of June 30, 2026, compared to a loss of 2,306 K€ as of June 30, 2025.

As of June 30, 2026, the ABIONYX Pharma Group's consolidated cash and cash equivalents stood at €26.9 million following the financing transaction announced on June 18 and prior to receiving Research Tax Credits and grants under the France 2030 plan.

The Company notes that it is a recipient of the “i-Démo” call for projects under the France 2030 plan and has secured €8.7 million in government funding to combat sepsis—the third leading cause of death worldwide—of which €6.2 million remains to be received.

Outlook

The Company remains fully focused on executing its strategy and rigorously implementing its announced programs, particularly GMP production for sepsis and LCAT deficiency, as well as preparing for the next regulatory steps related to the Phase 2b trial for sepsis.

Selected Financial Information

(as of June 30, 2026 / Consolidated financial statements in accordance with IFRS)

M€	June 30, 2026	June 30, 2025
Revenue	1.93	2.12
Cost of goods and services sold	-1.83	-1.89
R&D expenses	-0.57	-0.69
Administrative and selling expenses	-1.81	-1.88
Operating Income	-2.27	-2.33
<i>Financial Income</i>	0.05	0.13
<i>Financial expenses</i>	-2.59	-0.10
Financial Income	-2.54	0.03
Net Income	-4.81	-2.31

M€	June 30, 2026	June 30, 2025
Net cash flow from operating activities	-2.04	-1.70
Net cash flow from investing activities	-0.05	-0.16
Net cash flow from financing activities	25.44	2.00
Change in cash and cash equivalents	23.35	0.14
Cash and cash equivalents at the end of the period	26.87	3.38

The half-year financial report as of June 30, 2026, has been made available to the public and on the Autorité des Marchés Financiers website.

About ABIONYX Pharma

ABIONYX Pharma is a next-generation biopharmaceutical company focused on sepsis and critical care, developing breakthrough biotherapies for serious diseases for which there are no effective treatments. Through its proprietary apoA-I-based technology platform, ABIONYX Pharma designs innovative biopharmaceuticals and next-generation HDL vectors that target the immune-inflammatory dysregulation at the core of sepsis and other severe diseases. Driven by recognized scientific expertise, a differentiated pipeline, and an expanding global clinical network, ABIONYX Pharma aims to redefine therapeutic standards for sepsis and become a key player in intensive care.

Contacts:

ABIONYX Pharma
infos@abionyx.com

Disclaimer:

The statements contained in this document may constitute “forward-looking statements.” These statements include all matters that are not historical facts and can generally, but not always, be identified by the use of words such as “believes,” “expects,” “should,” “anticipates,” “intends to,” “estimates,” “is expected to,” “will continue to,” “may,” “is likely to,” “forecasts,” or similar expressions, including their variations, negative forms, or comparable terms.

Forward-looking statements are not guarantees of future performance; they involve a number of known and unknown risks, uncertainties, and other factors, and ABIONYX Pharma’s actual operating results, financial condition, and the development of the industry in which it operates may differ materially from those indicated or implied by the forward-looking statements contained in this document. Furthermore, even if ABIONYX Pharma’s operating results and financial condition, as well as developments in the industry in which it operates, are consistent with the forward-looking statements contained in this document, such results or developments are not necessarily indicative of results or developments in subsequent periods. ABIONYX Pharma does not undertake to publicly update or revise any forward-looking statements that may be made in this document, whether as a result of new information, future events, or otherwise.